Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R

被引:3
作者
Cabarrou, B. [1 ]
Jouin, A. [2 ]
Boher, J. M. [3 ]
Kramar, A. [2 ]
Filleron, T. [1 ]
机构
[1] Inst Claudius Regaud, Bur Essais Clin, Cellule Biostat, IUCT O, F-31059 Toulouse 9, France
[2] Ctr Oscar Lambret, F-59020 Lille, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
关键词
Complication; Health state; Survival analysis; Prevalence function; R software; CENSORED SURVIVAL-DATA; CANCER; TESTS;
D O I
10.1016/j.cmpb.2014.12.006
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The importance of evaluating complications and toxicity during and following treatment has been stressed in many publications. In most studies, these endpoints are presented descriptively and summarized by numbers and percentages but descriptive methods are rarely sufficient to evaluate treatment-related complications. Pepe and Lancar developed Prevalence and Weighted Prevalence functions which take into account the duration and the severity of complication unlike conventional methods of survival analysis or competing risks which are limited to the time to first event. The purpose of this paper is to describe features and use of two R functions, main.preval.func and main.wpreval.func, which were designed for the analysis of survival adjusted for quality of life. These functions compute descriptive statistics, survival and competing risks analysis and especially Prevalence and Weighted Prevalence estimations with confidence intervals and associated test statistics. The use of these functions is illustrated by several examples. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:298 / 308
页数:11
相关论文
共 18 条
[1]  
AARONSON N.K., 1996, QUALITY LIFE PHARMAC, V2nd, P179
[2]  
[Anonymous], 2013, CMPRSK SUBDISTRIBUTI
[3]   Audit of effectiveness of routine follow-up clinics after radiotherapy for cancer -: A report of the REACT working group of ESTRO [J].
Ataman, ÖU ;
Barrett, A ;
Davidson, S ;
De Haas-Kock, D ;
Dische, S ;
Dubray, B ;
Grillo, IM ;
Kramar, A ;
Haie-Meder, C ;
Heeren, G ;
Hideghety, K ;
LeVay, J ;
Maher, J ;
Marcenaro, M ;
Muller, RP ;
Reguerio, CA ;
Saunders, MI ;
Turesson, I ;
Van Houtte, P ;
Vitale, V .
RADIOTHERAPY AND ONCOLOGY, 2004, 73 (02) :237-249
[4]   Randomized controlled trials in health technology assessment: Overkill or overdue? [J].
Bentzen, Soren M. .
RADIOTHERAPY AND ONCOLOGY, 2008, 86 (02) :142-147
[5]  
Development Core Team, 2006, R LANG ENV STAT COMP
[6]  
Gelber E.D., 1987, ADJUVANT THERAPY CAN, P455
[7]   COSTS AND BENEFITS OF ADJUVANT THERAPY IN BREAST-CANCER - A QUALITY-ADJUSTED SURVIVAL ANALYSIS [J].
GOLDHIRSCH, A ;
GELBER, RD ;
SIMES, RJ ;
GLASZIOU, P ;
COATES, AS .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :36-44
[8]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[9]   A CLASS OF RANK TEST PROCEDURES FOR CENSORED SURVIVAL-DATA [J].
HARRINGTON, DP ;
FLEMING, TR .
BIOMETRIKA, 1982, 69 (03) :553-566
[10]  
Kalbfleish J, 1980, STAT ANAL FAILURE TI